SecBot SecBot
8-K ·Filed Nov 3, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed13d 11h ago SEC0001628280-26-069493
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor enrollment updates for the PROPEL-IPF Phase 2 trial and any data readouts for PIPE-791 in IPF or chronic pain. The cash runway through mid-2029 removes near-term financing risk, but the widening loss reflects increased trial spending with no revenue on the horizon.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CTNM drug pipeline →

PIPE-791

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 4-5 years away, if successful. The Phase 2 PROPEL-IPF trial is estimated to complete in June 2028, and a Phase 3 program and regulatory filing would follow, meaning potential approval is likely in the 2030-2032 timeframe at the earliest.
Next catalyst
None dated

What to watchPIPE-791 is a mid-stage asset with no near-term binary catalyst; the next major event is the Phase 2 PROPEL-IPF readout estimated for mid-2028. The competitive landscape shifted significantly on October 12, 2026, when BMS's admilparant succeeded in Phase 3 for IPF, potentially becoming the first approved LPAR1 antagonist. Investors should watch for enrollment completion updates and whether Contineum can differentiate PIPE-791 on safety, dosing convenience, or CNS indications (chronic pain, MS) where BMS's compound may not compete.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$9.79
T+0 close · Nov 3, 2026 · via day close
Latest settled
+10.01%
T+5 · $10.77 · next T+20 in 16d
Vs SPY
+10.92%
α at T+5
Latest observation
+1.69%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $9.79entry
  2. T+1 · 12d ago −10.01%α −5.60% · $8.81
  3. T+5 · 6d ago +10.01%α +10.92% · $10.77
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Contineum Therapeutics reported Q3 2026 financial results with a net loss of $18.7M, wider than the $12.8M loss in Q3 2025, driven by a 45% increase in R&D expenses to $16.0M for the PIPE-791 IPF program. Cash and securities stood at $244.5M, with a projected runway through mid-2029. No revenue or EPS consensus beat/miss is applicable as the company is a pre-revenue clinical-stage biotech.

Key Financial Metrics

EPS
−$0.49

Key Facts

  • Net loss of $18.7M for Q3 2026 vs $12.8M in Q3 2025
  • R&D expenses $16.0M, up 45% YoY driven by PIPE-791 IPF program
  • Cash, cash equivalents and marketable securities $244.5M as of Sep 30, 2026
  • Cash runway projected through mid-2029, one year past estimated IPF trial completion
  • PROPEL-IPF Phase 2 trial for PIPE-791 has over 100 sites in 16 countries
  • Weighted-average diluted shares 38,390,234 in Q3 2026 vs 28,115,548 in Q3 2025

Financial Impact

Net loss widened by $5.9M YoY; cash burn $18.7M per quarter; cash runway through mid-2029

net losscashR&D expenses

Risk Factors

  • No approved products or revenue; dependent on clinical trial success
  • Heavy reliance on PIPE-791 and PIPE-307, both in early clinical stages
  • R&D expenses expected to continue increasing significantly
  • Reliance on Janssen/Johnson & Johnson for PIPE-307 development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-069493
Document: ctnm-20261103.htm0001628280-26-069493
Document: 0001628280-26-069493-index-headers.html0001628280-26-069493
Document: 0001628280-26-069493-index.html0001628280-26-069493
Document: 0001628280-26-069493.txt0001628280-26-069493
8-K Data (Synthetic)0001628280-26-069493

US Market Status

Market Closed · Opens in 5h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026